Articles From: Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants to Immunomedics Provides Update on Phase 2 Study of Isactuzumab Govitecan in Patients With Diverse Metastatic Solid Cancers


2014/11/25
Immune has raised total gross proceeds of $9.625 million in November 2014 NEW YORK and HERZLIYA PITUACH, Israel, Nov.
Sign-up for Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants investment picks
2014/11/20
NEW YORK and HERZLIYA PITUACH, Israel, Nov.
Sign-up for Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock investment picks
2014/11/19
NEW YORK and HERZLIYA PITUACH, Israel, Nov.
Sign-up for Immune Pharmaceuticals Inc. Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock investment picks
2014/11/26
Immune has raised now total gross proceeds of $10.685 million in November 2014 NEW YORK and HERZLIYA PITUACH, Israel, Nov.
Sign-up for Immune Pharmaceuticals Inc. Completes Underwriter's Exercise Of Partial Over-Allotment Option investment picks
Immune developing personalized medicine drugs for auto-immune diseases and cancer NEW YORK and HERZLIYA PITUACH, Israel , Nov.
Sign-up for Immune's CEO To Present on Personalized Medicine at the 2014 NY/ NJ CEO Biotech Conference investment picks
2014/11/10
LOS ANGELES , Nov.
Sign-up for ImmunoCellular Therapeutics Announces Third Quarter 2014 Financial Results investment picks
2014/11/14
Continued Positive Trends in Overall Survival and Progression-Free Survival; Phase 3 Registration Program Anticipated to Start 1H15; Company to Host Conference Call on Tuesday, November 18th LOS ANGELES , Nov.
Sign-up for ImmunoCellular Therapeutics Presents Updated ICT-107 Phase II Data at the Society for Neuro-Oncology Annual Meeting 2014 investment picks
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche has announced top-line results of its Phase III MARIANNE study.
Sign-up for ImmunoGen Reports Roche Has Provided an Update on the MARIANNE Trial investment picks
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Again Named One of The Boston Globe’s Top Places to Work investment picks
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Announces 2015 Outlook for Product Pipeline investment picks
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the data presentations on Company and partner experimental therapies to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 6-9, 2014 in San Francisco, CA.
Sign-up for ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition investment picks
ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 33 rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Sign-up for ImmunoGen, Inc. Announces Webcast of Presentation at the 33rd Annual J.P. Morgan Healthcare Conference investment picks
ImmunoGen, Inc .
Sign-up for ImmunoGen, Inc. Reports First Quarter Fiscal Year 2015 Financial Results investment picks
ImmunoGen's stock (IMGN) plunged to a more than four-year low in very-active trade Friday afternoon, after Leerink Partners downgraded it to market perform from outperform, following disappointing trial results for Roche Holding's (RHHBY) . Leerink analyst Michael Schmidt also cut his stock price target to $7 from $15. Roche's drug Kadcyla utilizes ImmunoGen's antibody-drug conjugate technology.
Sign-up for ImmunoGen's stock plunges after Roche's disappointing trial results prompts downgrade investment picks
MORRIS PLAINS, N.J., Oct.
Sign-up for Immunomedics Announces Conference Call and Webcast for First Quarter Fiscal 2015 Financial Results investment picks
MORRIS PLAINS, N.J., Nov.
Sign-up for Immunomedics Announces First Quarter Fiscal 2015 Results and Clinical Program Developments investment picks
MORRIS PLAINS, N.J., Nov.
Sign-up for Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus investment picks
MORRIS PLAINS, N.J., Dec.
Sign-up for Immunomedics Announces Outcome of 2014 Annual Meeting of Stockholders investment picks
MORRIS PLAINS, N.J., Oct.
Sign-up for Immunomedics Announces Presentations at the 2014 European Association of Nuclear Medicine Congress investment picks
MORRIS PLAINS, N.J., Nov.
Sign-up for Immunomedics Announces Six Presentations on Epratuzumab in Lupus at Leading Rheumatology Meeting investment picks
MORRIS PLAINS, N.J., Jan.
Sign-up for Immunomedics Appoints Dr. Francois Wilhelm Chief Medical Officer investment picks
BARCELONA, Spain, Nov.
Sign-up for Immunomedics Presents Clinical Data on Novel Antibody-Drug Conjugates for Solid Cancer Therapy investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants to Immunomedics Provides Update on Phase 2 Study of Isactuzumab Govitecan in Patients With Diverse Metastatic Solid Cancers
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent